Hjem › Burkitts lymfom › Minnesota › Minneapolis
Kliniske studier for Burkitts lymfom i Minneapolis, MN
9 studier for Burkitts lymfom søker deltakere på steder i og rundt Minneapolis (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
RekruttererFase 2
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
RekruttererFase 3
- Abbott-Northwestern Hospital, Minneapolis
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
RekruttererFase 2
- University of Minnesota/Masonic Cancer Center, Minneapolis
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RekruttererFase 1
- University of Minnesota, Minneapolis
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
RekruttererFase 2
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
RekruttererFase 3
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
RekruttererFase 2
- Children's Hospitals and Clinics of Minnesota, Minneapolis
Allo HSCT Using RIC and PTCy for Hematological Diseases
RekruttererFase 2
- Masonic Cancer Center at University of Minnesota, Minneapolis
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RekruttererFase 2
- Masonic Cancer Center at University of Minnesota, Minneapolis
Burkitts lymfom-studier i andre byer
- Houston, TX21 studier
- Milwaukee, WI16 studier
- Philadelphia, PA16 studier
- New York City, NY14 studier
- Chicago, IL14 studier
- Cincinnati, OH12 studier
- Atlanta, GA12 studier
- Seattle, WA11 studier
- Durham, NC10 studier
- Boston, MA10 studier
- Los Angeles, CA10 studier
- Aurora, CO10 studier
Andre studier i Minneapolis
- Brystkreft27 studier
- Ikke-småcellet lungekreft26 studier
- Eggstokkreft24 studier
- Prostatakreft23 studier
- Kreft (alle typer)22 studier
- Hjertesvikt21 studier
- Lungekreft20 studier
- Akut myelogen leukemi20 studier
- Kolorektal kreft19 studier
- Endometriekreft18 studier
- Parkinsons sykdom17 studier
- Kardiovaskulær sykdom15 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.